Method of determining clinical effectiveness in cervical cancer |
|
|
IPC classes for russian patent Method of determining clinical effectiveness in cervical cancer (RU 2464576):
Method for describing nature of arrested sexual development in boys in puberty with growth retardation / 2462720
Examination results are used to detect boys with the absence or insufficiency of blood concentrations of at least two of three hormones (luteinising hormone, follicle-stimulating hormone, total testosterone) to be used for the clinical course of transcranial magnetic therapy. The concentration of all hormones are evaluated in 1-1.5 months, and if observing increase of the concentrations of at least two hormones, including testosterone by min. 25% from the initial values, a functional nature of arrested sexual development is stated. If observing no increase or increase of the concentrations of two hormones, including testosterone by max. 25% from the initial values, an organic nature of arrested sexual development is stated.
 Diagnostic technique for idiopathic nasal breathing irregularities in pregnant women / 2456604
Blood serum of a pregnant woman is examined for the oestradiol concentration by enzyme-linked immunosorbent assay. Observing the oestradiol concentrations exceeding normal values according to weeks of gestation in 1.4 times and more enables stating idiopathic nasal breathing irregularities accompanying a period of pregnancy.
Method for prediction of level of efficiency of reduction of manifestation severity of atopic dermatitis / 2453851
Pre-therapy blood plasma is analysed for immunoglobulin E, adrenocorticotrophin and endorphin, the index SCORAD dynamics is determined by formula: Dsk=1.34147-0.000820741*IgE-0.00382642*ACTP+0.0209401*endorphin wherein IgE is the level of acute blood plasma immunoglobulin E mIU/ml; ACTP is the level of acute blood plasma adrenocorticotrophin ng/l. If observing the Dsk value exceeding 1.18, a prognosis of improving clinical dynamics of recovery is favourable; the conventional therapy is considered to be sufficient. The Dsk value being equal to 1.18 or less, the improving clinical dynamics of recovery is unfavourable, the intensified therapeutic scheme for atopic dermatitis is considered to be preferential.
 Method for identification and classification of 3-oxosteroids and their metabolites in doping test of sportsmen / 2452967
Blood plasma is examined for the presence and the position of double bonds and the related differences in structural characteristics. Common and examined steroids are chemically modified by a carboxyl group (oximes); their mass spectra are read out and recorded; characteristic ions (lc) and neutral loss (Do) are specified in the mass spectra. The specified lc and Do values are related to those specific for common 3-oxosteroid oximes by the absolute value. Herewith it is only the similar lc and Do values from both sides differing by 0.3% and less that are taken into consideration; the comparison results are used to identify 3-oxosteroid oximes.
Method of antenatal prediction of consequences of perinatal lesions of nervous system in children / 2449287
Clinical examination of pregnant woman is carried out, additionally performed are Stange's and Hench's functional respiratory tests in early period at terms of 11-19, 21-29, 31-39 weeks of gestation period, also in dynamics in I and III trimesters determined are indices of blood hormonal spectrum: T4, TSH, T3, cortisole, vitamin E, insulin, indices of lipid peroxidation and antioxidative blood activity, blood indices - hemoglobin, platelets, total protein, fibrinogen. Analysis of risk factors is carried out, their gradations and numerical values are determined and prognostic coefficients S1 and S2 are calculated by formulas. If S1>S2, presence of moderate or severe CNS lesion in children at the age of 4 is predicted. If S1<S2, presence of light degree of severity, or absence of consequences of CNS lesion in children at the age of 4 is predicted.
Method for prediction of dysthyroidism / 2446401
Method involves woman's pre-delivery blood serum examination for nitrogen oxide and relaxin that is followed by calculation of the NO/relaxin relation. If the relation is 3.6 and less, dysthyroidism is predicted.
Method of predicting development of cerebral metastases in case of lung cancer in women / 2439579
In women in tissue of lung malignant tumour after radical surgery in pulmonectomy volume and in intact lung tissue, obtained from ablated from lung section of the same lung, level of progesterone is determined. If it reduces in tumour in 5 times and more relative the level of progesterone in intact lung tissue, development of cerebral lung cancer metastases in women within the term from 3 to 8 months is predicted.
Method of diagnosing androgenic deficiency / 2439578
In blood serum bioavailable testosterone fraction bound to albumin is determined. If its value is lower than 185.7 pg/ml, disease is diagnosed.
 Method of predicting survival potential of patients with malignant gliomas / 2439577
In patient's urine content of 6-sulfatoximelatonin is determined. If determined content of 6-sulfatoximelatonin after operation before complex treatment equals 292.7 nmol/ml survival to 2.3±0.5 months is predicted, if 22.4 nmol/ml is determined, survival for more than 12 months is predicted. If after chemical therapy determined content of 6-sulfatoximelatonin equals 268.2 nmll/ml, predicted survival time equals to 2.1±0.6 months, if content is 32.8 nmol/ml - more than 12 months. If after a month after treatment determined content of 6-sulfatoximelatonin equals 479.3 nmol/ml predicted is survival for 1.2±0.5 months, in case of 37.4 nmol/ml - survival for more than 12 months.
Method for prediction of cervical cancer metastases / 2436102
In 10-14 days following a surgical removal of a tumour in a patient, daily urine is analysed for sex hormones: oestradiol and pregnandiol. Then, they are related to each other. If the value exceeds 0.8, the onset of metastases or a recurrent disease for the following one and a half or two years is predicted. If the relation is less than 0.8, a metastases-free and recurrence-free period for more than 8-10 years is predicted.
Diagnostic technique for prostate cancer / 2464574
Digital rectal examination is applied to localise a prostate induration (INp). If observing the prostate induration, the value equal to 1 is assigned to the value INp, while the absence of the induration shows the value equal to 0. The ultrasonic data are used to measure prostate volume (Vp), cm3. Patient's blood serum is examined for a level of total prostate-specific antigen (Ltpsa), ng/ml. Additionally, the primary histologic findings (PHF) of the prostate biopsy materials are studied. If observing high-grade prostatic intraepithelial neoplasia (PIN) as shown by the primary histologic findings of the prostate biopsy materials, the value equal to 1 is assigned to the PHF; while low-grade PIN or the absence thereof enables assigning the value equal to 0. The diagnostic coefficient (Cd) is calculated by formula: Cd=9.01-9.62 (INp)-0.015 (Vp)-0.27 (PHF)-9.51 [(Ltpsa):(Vp)]. The value Cd<0 enables diagnosing prostate cancer in the patients with the cancer-negative primary histologic findings.
Differential diagnostic technique for benign prostate hyperplasia and prostate cancer / 2464569
Ultrasonic data are used to measure prostate volume. Thereafter patient's blood is examined for levels of total and free prostate-specific antigen (PSA). Additionally, the age is patient reported. It is followed by calculating a diagnostic coefficient (Cd) by formula: Cd=6.14-0,18(A)-3.19(Ltpsa)+7.66(Ltpsa)+140[(Ltpsa):(Lp)]+0.09(Lp) wherein A is the patient's age, completed years; (Ltpsa) is the level of total PSA, ng/ml; (Lspsa) is the level of free PSA, ng/ml; (Lp) is prostate volume, cm3. If Cd>0, benign prostate hyperplasia is diagnosed. The value Cd<0 enables diagnosing prostate cancer.
Method for determining early predictors of onset of differentiation syndrome in treating patients suffering acute promyelocyte leukemia / 2461003
Method for determining early predictors of the onset of differentiation syndrome (DS) in treating the patients suffering acute promyelocyte leukemia involves measuring body temperature, counting leukocytes, promyelocytes in peripheral blood and thrombocytes, evaluating a hemoglobin level, an activated partial thromboplastin time (APTT) index anf a prothrombin index (PTI), the concentrations of fibrinogen, urea and creatinine; if observing febrile temperature, decreased thrombocyte count less than 20*109/l (deep thrombocytopenia), prolonged APTT index with respect to the norm before transretinoic acid (ATRA) therapy, decreased hemoglobin to 73 g/l if prescribed after developing DS, persistent hypofibrinogenemia and deep thrombocytopenia combined with increasing ures and creatinine in progression as compared with the reference values regardless of peripheral blood leukocyte and promyelocyte count, possibility of developing differentiation syndrome may likely stated.
 Cancer biomarkers / 2460075
What is presented is a diagnostic and monitoring technique for prostate cancer progression involving detection and/or evaluation of a homeodomain-containing transcription EN-2 factor or its urinary fragment, and comparison the amount of said homeodomain-containing transcription factor in a tested urine sample with that found in the reference sample taken from a normal healthy subject wherein increasing the level of homeodomain-containing transcription factor or its fragment found in the tested sample is an indicator of the fact that the disease is progressing or has started. What is offered is using in vitro said homeodomain-containing transcription factor or its fragment to be detected in urine as a prostate cancer biomarker.
 Pharmaceutical compositions able to induce cancer cell apoptosis for diagnosing and treating b-cell chronic lymphocytic leukaemia / 2454245
Group of inventions refers to medicine, and concerns pharmaceutical compositions able to induce cancer cell apoptosis for diagnosing and treating B-cell chronic lymphocytic leukaemia. Substance of the inventions involves the pharmaceutical compositions for treating B-cell chronic lymphocytic leukaemia containing an active ingredient presented by a humanised monoclonal antibody T1h from a secreting hybridoma IOR-TIA under depositary No. ECACC 96112640, identifying a leukocyte differentiation antigen CD6. A diagnostic reagent also contains said antibody.
 Sensitin for erythrocytic diagnosticum for diagnosis of malignant growths and method for making it, erythrocytic diagnosticum for diagnosis of malignant growths and method for making it and diagnostic technique for presence of malignant growths with using such erythrocytic diagnosticum / 2452501
Invention refers to medicine, and concerns diagnosis of oncological diseases. What is developed is an erythrocytic diagnosticum containing formalised sheep erythrocytes sensitised by a mixture of fractions of low-molecular protein compounds of molecular weight 3000-15000 Da recovered from blood serum of pregnant horses on their 20-60th day of pregnancy, and reacting with proteins stimulating malignant cell proliferation. A method for producing the erythrocytic diagnosticum for diagnosing the presence of malignant growths involving sensitisation of a suspension of formalised mammal erythrocytes in a buffer solution of pH 6.4-6.6 with sensitin. The sensitin is presented by the mixture of fractions of low-molecular protein compounds of molecular weight 3000-15000 Da recovered from blood serum of pregnant horses in early pregnancy, and interacting with proteins stimulating malignant cell proliferation. A diagnostic technique for malignant growths with using the erythrocytic diagnosticum.
Method for prediction of developing metachronous colon cancer / 2447447
Carcinoembryonal antigen is analysed in tissue of malignant growth in colon. The carcinoembryonal antigen level in tissue of the malignant growth is equal to 1186±50.2 ng/g of tissue, a probability of the developing metachronous malignant process in the patients with colon cancer is predicted.
 Method for prediction of children pyelonephritis development with renal system anomalies / 2442987
FIELD: medicine. SUBSTANCE: method involves the measurement of neutral α-glucosidase and L-alanylaminopeptidase in patients urine. With increased activity level of neutral α-glucosidase over 25.20±1.76 μmole of maltose/μmole of creatinine per hour in children below age of 7 and with level of its activity over 16.77±1.64 μmole of maltose/μmole of creatinine per hour in children over age of 7, as well as increased activity of L-alanylaminepeptidase ofver 0.97±0.12 ncat/mole creatinine regadless of age the damage of epithelium of proximal renal channel predictive of pyelonephritis development in children with renal system anomalies. EFFECT: higher diagnosis accuracy of children pyelonephritis with renal system anomalies development. 1 dwg, 1 tbl, 3 ex, 1 dwg  Method for assessment of renal survival rate in patients with chronic glomerulonephritis by interleukin gene polymorphism values / 2431149
DNA is recovered from peripheral venous blood; interleukin gene alleles and genotypes are detected. Decreasing renal survival rate in patients with chronic glomerulonephritis is concluded in the following cases: - detection of carriage of interleukin 1A -889C/T IL-1A gene allel-889S or interleukin 10-592C/AIL-10 gene allel-592A; - detection of carriage of interleukin 1 B -511 C/T IL-1B gene allel-51 IT in a combination with nephrotic syndrome for the first examination and observed arterial hypertension during CGN; - detection of 4R/4R genotype of interleukin 1 VNTR IL-lRa receptor antagonist gene.
 Circulating tumour cell assay / 2429486
There are offered methods for determining therapeutic efficacy of insulin-like growth factor-1 receptor (IGF-1R) antagonists. The methods are based on detecting and counting the IGF-1R expressing circulating tumour cells.
 Method for predicting uveal melanoma metastasis spread with apoptosis markers bax and bcl-2 / 2244934
Method involves carrying out immunohistochemical analysis of withdrawn tumor cells to determine percentage of cells showing Bax expression with respect to general quantity of cancer cells in vision field, percentage of cells showing Bcl-2 expression, index disclosing relation between the values. The index value being less than 1.0, high metastasis progress probability is to be predicted.
|
FIELD: medicine. SUBSTANCE: one week after the termination of polychemotherapy, daily urine is examined for the amount of cortisol and cortisone, while blood is examined for adrenocorticotropic hormone. It is followed by calculating the relation of total cortisol and cortisone to adrenocorticotropic hormone. If the derived value is 0.74 and higher, high responsiveness to chemopreparations is stated. EFFECT: use of the method enables selecting the most adequate complex of anticancer chemopreparations for each patient, performing a surgical intervention in more conservative extent. 1 ex
The invention relates to medicine, in particular to cancer, and can be used in the treatment of patients with cervical cancer. Known way to predict individual sensitivity to XT by definition in the blood of patients before treatment concentrations of pituitary hormones - follicle-Stimulating and luteinizing (patent No. 1827639 bull. 26. from 15.07.93 - Teemoista, Mebazaa "method for determining the sensitivity of individual patients with ovarian cancer stage 3-4 to chemohormonal"). However, the use of the known method is not always possible, as suggested regimens for the treatment of cervical cancer do not use hormonal drugs. There is a method of forecasting results lekarstvennoi therapy in patients with BREAST CANCER on discriminant functions using indicators (hormones and catecholamines defined daily urine of patients - the amount of 17 - ketosteroids, dehydroepiandrosterone, norepinephrine, epinephrine (Unibanco, Aigeria, SEO, Timkovsky, Ligularia "explore the possibilities of predicting the effectiveness of anticancer therapy on the basis of the original neuroendocrine indicators." The book "Autolymphocyte and other issues of Oncology". M, 1997). The method is quite effective, it gives the possibility of the ability to determine the most effective treatment regimen. However, it is very time consuming, requires a minimum of 2 weeks for all analyses, the consumption of significant quantities of reagents. The aim of the invention is the determination of individual sensitivity to chemotherapy in patients with cervical cancer of reproductive age. This objective is achieved in that one week after completion of chemotherapy in daily urine of patients are determined by the content of cortisol and cortisone and blood content of adrenocorticotropic hormone (ACTH). Next, calculate the ratio of the sum of cortisol and cortisol to ACTH. When the value of the indicator below 0,60 ascertain the lack of sensitivity of tumor cells to chemotherapy, and when the value of this index is 0.74 and above note the high sensitivity to chemotherapeutic drugs. Analysis of the known methods of determining the effectiveness of tumor cells to chemotherapeutic drugs and claimed allows to establish the existence of novelty and difference of the latter. The novelty of the proposed method of determining the effectiveness of treatment of cervical cancer is that patients of reproductive age with cancer of the cervix determine the individual sensitivity of each patient used antitumor drugs. In open sources information of Russia, CIS and abroad analogion the x ways could not be found. The developed method is industrially applicable. It can be used in health care facilities General medical network, as it can be reproduced and repeated many times. The method is as follows. After being diagnosed with cancer of the cervix are polychemotherapy one of the proposed standard schemes. Then a week after the last drug administration in daily urine of the patient determine the amount of cortisol and cortisone and blood adrenocorticotropic hormone. Next, determine the ratio between the amount of cortisol and cortisone to adrenocorticotropic hormone. When the value of the indicator below 0,60 ascertain the lack of sensitivity of tumor cells to chemotherapy, and when the value of this index is 0.74 and the above-noted high sensitivity to chemotherapeutic drugs. An example of a specific implementation, a method of determining the effectiveness of treatment of cervical cancer can serve as a statement of history Patient C., 27 years old, medical history, No. 7686/and enrolled in the gynecology Department 10.11.2001, for examination. Complaints when applying for rich whites. In the anamnesis the patient childbirth, abortion no, not pregnant. In March 2001 on the periodic health examination found cervical erosion, underwent conservative treatment without E. the reaction. 10.11.2001, directed at the cancer Institute with suspected cancer of the cervix. Upon receipt 13.11.2001, mirrors: cervix cylindrical shape, on the front lip of the cervix is a small exophytic tumor of 1.5×1.5 cm Rectovaginal: the uterus is a small mobile left appendages are not defined, right - testoste. Produced biopsy of cervical tumors. Histological analysis from 11.11.2001, No. 100899. Squamous cell carcinoma without keratinization. Diagnosis: cervical cancer .Ib CL gr. II, exophytic T1NoMo. From the proposed intervention and radiation therapy the patient refused. In the gynecology Department of RNII with 29.11.2001 he had undergone chemotherapy. Just received 100 mg methotrexate 2000 mg of cyclophosphamide + 1000 mg 5-fluorouracil. 12.12.2001 daily urine determined number of cortisol and cortisone and blood content of ACTH, determined by dividing the amount of cortisol and cortisol to ACTH. The amount of cortisol and cortisone was 0.70, and the ratio of to ACTH 0,82. After the treatment, when viewed in the mirrors found: the cervix is not changed, no tumor, the allocation of scarce. Bimanual: the uterus is normal in size, limited to mobile, parametrium available. Produced by cytological examination of a scraping from the surface of the cervix. Analysis No. 236/ - signs of tumors and atypical the notches Cytology was not found. 30.12.2001, the patient was discharged home with the purpose of the control turnout in 3 months. 14.03.2002 - at the control examination the patient feels well. Within 2 years the patient was subjected to systematic examination and signs of recurrence of the disease was not. Can start to their previous employment. Developed by the method determined by the efficiency of anticancer chemotherapy in 16 patients with cervical cancer. In cases where the ratio between the amount of cortisol and cortisone to adrenocorticotropic hormone exceeded 0.74 and higher patients to date in satisfactory condition. Technical and economic efficiency of the method of determination of efficiency of treatment of cervical cancer is the ability to choose the most suitable for each patient is complex anticancer chemotherapy; surgical interventions in more moderate amounts. The method of determining the effectiveness of treatment of cervical cancer, including chemotherapy and biochemical study of hormones, characterized in that one week after the end of chemotherapy in daily urine to determine the amount of cortisol and cortisone and blood - adrenocorticotropic hormone, then calculate the amount of cortisol and cortisone to adrenocorticotropic hormone; when led is ine of this index is 0.74 and above note the high sensitivity to chemotherapeutic drugs.
|